JA
Live price temporarily unavailable.
Price history
Jazz Pharmaceuticals (JAZZ) is a Health Care company in the Russell 1000. Latest news and coverage below.
Jazz Pharmaceuticals revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.49B | $1.62B | $1.89B | $2.16B | $2.36B | $3.09B | $3.66B | $3.83B | $4.07B | $4.27B |
| Growth (year over year) | +12.3% | +8.8% | +16.8% | +14.3% | +9.3% | +30.9% | +18.3% | +4.8% | +6.1% | +4.9% |
| Operating income | $591.7M | $528.8M | $614.8M | $532.4M | $378.1M | $170.3M | −$65.5M | $578.6M | $716.6M | −$430.2M |
| Operating margin | 39.8% | 32.7% | 32.5% | 24.6% | 16.0% | 5.5% | −1.8% | 15.1% | 17.6% | −10.1% |
| Net income | $396.8M | $487.8M | $447.1M | $523.4M | $238.6M | −$329.7M | −$224.1M | $414.8M | $560.1M | −$356.1M |
| Net margin | 26.7% | 30.1% | 23.6% | 24.2% | 10.1% | −10.7% | −6.1% | 10.8% | 13.8% | −8.3% |
| EPS (diluted) | $6.41 | $7.96 | $7.30 | $9.09 | $4.22 | −$5.52 | −$3.58 | $6.10 | $8.65 | −$5.84 |
| Balance sheet | ||||||||||
| Cash and equivalents | $366.0M | $386.0M | $309.6M | $637.3M | $1.06B | $591.4M | $881.5M | $1.51B | $2.41B | $1.39B |
| Total assets | $4.80B | $5.12B | $5.20B | $5.54B | $6.54B | $12.3B | $10.8B | $11.4B | $12.0B | $11.7B |
| Total liabilities | $2.92B | $2.41B | $2.45B | $2.43B | $2.88B | $8.33B | $7.75B | $7.66B | $7.92B | $7.34B |
| Long-term debt | $1.99B | $1.54B | $1.56B | $1.57B | $1.85B | $6.02B | $5.69B | $5.11B | $6.08B | $4.33B |
| Shareholders' equity | $1.88B | $2.71B | $2.76B | $3.11B | $3.66B | $3.97B | $3.09B | $3.74B | $4.09B | $4.32B |
| Cash flow | ||||||||||
| Operating cash flow | $592.4M | $693.1M | $798.9M | $776.4M | $899.6M | $778.5M | $1.27B | $1.09B | $1.40B | $1.36B |
| Capital expenditure | $9.69M | $28.9M | $20.4M | $40.1M | $15.0M | $27.6M | $29.0M | $24.0M | $38.1M | $58.8M |
| Free cash flow | $582.7M | $664.1M | $778.5M | $736.3M | $884.6M | $750.9M | $1.24B | $1.07B | $1.36B | $1.30B |
| Share buybacks | $278.3M | $98.8M | $523.7M | $301.4M | $146.5M | $0 | $54.0K | $269.8M | $311.4M | $125.0M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.05B | $1.09B | $897.8M | $1.05B | $1.13B | $1.20B | $1.07B | $1.21B |
| Growth (year over year) | +8.5% | +7.5% | −0.5% | +2.1% | +6.7% | +10.1% | +19.1% | +15.5% |
| Operating income | $260.2M | $190.8M | −$55.9M | −$686.4M | $57.5M | $254.6M | $336.6M | $248.2M |
| Operating margin | 24.7% | 17.5% | −6.2% | −65.6% | 5.1% | 21.2% | 31.5% | 20.5% |
| Net income | $215.1M | $191.1M | −$92.5M | −$718.5M | $251.4M | $203.4M | $293.1M | $192.8M |
| Net margin | 20.4% | 17.6% | −10.3% | −68.7% | 22.3% | 17.0% | 27.4% | 16.0% |
| EPS (diluted) | $3.42 | $2.97 | −$1.52 | −$11.74 | $4.08 | $3.34 | $4.43 | $2.78 |
| Balance sheet | ||||||||
| Cash and equivalents | $2.22B | $2.41B | $1.86B | $1.19B | $1.33B | $1.39B | $1.84B | $1.62B |
| Total assets | $12.3B | $12.0B | $11.5B | $10.9B | $11.4B | $11.7B | $11.9B | $11.1B |
| Total liabilities | $8.08B | $7.92B | $7.36B | $7.24B | $7.40B | $7.34B | $7.33B | $6.28B |
| Long-term debt | $6.08B | $6.08B | $5.34B | $4.34B | $4.33B | $4.33B | $4.32B | $3.33B |
| Shareholders' equity | $4.17B | $4.09B | $4.17B | $3.71B | $3.96B | $4.32B | $4.53B | $4.80B |
| Cash flow | ||||||||
| Operating cash flow | $398.7M | $398.6M | $429.8M | $88.8M | $474.7M | $362.5M | $408.2M | $415.7M |
| Capital expenditure | $10.8M | $13.3M | $13.9M | $12.9M | $15.2M | $16.7M | $19.7M | $18.1M |
| Free cash flow | $388.0M | $385.3M | $415.9M | $75.9M | $459.4M | $345.8M | $388.5M | $397.6M |
| Share buybacks | $150.0M | $0 | — | — | $23.0K | $0 | — | — |
From Jazz Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Source: Wikipedia — Jazz Pharmaceuticals
- Headquarters
- Dublin, Ireland From SEC filings, Oct 2026
Recent News (7)
-
/C O R R E C T I O N -- Blue Bottle Coffee/ In the news release, Blue Bottle Coffee Debuts Notes in Repose, a Limited-Edition Vinyl Celebrating Coffee, Jazz and the Art of Composition, issued 29-Sep-2026 by Blue Bottle Coffee over PR Newswire, …
-
-
Annapolis Jazz & Roots Festival Offers Music, History and Culture November 6-15 ANNAPOLIS, Md., Sept. 24, 2026 /PRNewswire/ -- Annapolis Jazz & Roots is launching its fifth festival on the scenic shores of the Chesapeake Bay. Enjoy music, art, poetry and history on two weekends, …
-
Jazz Pharmaceuticals at Morgan Stanley conference: oncology drives growth
Jazz Pharmaceuticals at Morgan Stanley conference: oncology drives growth
-
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fa…
-
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fa…
-
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International